News Category
Helus Pharma appoints Regina Donohue as Chief People Officer and Dr. Suresh Durgam to its Scientific Advisory Board, strengthening its organizational ...
Helus Pharma reports enrollment completion in its pivotal Phase 3 APPROACH trial for HLP003 in major depressive disorder, with topline data expected i...
Helus Pharma's appointment of veteran biopharma leader Michael Halstead as CEO signals strategic preparation for Phase 3 results and commercialization...
Luke Van Der Veer's Website Rental Coaching program has expanded its local SEO training to 14 countries, enabling students to generate recurring reven...
Ireland has banned the use of electroconvulsive therapy on individuals under 18, a move praised by human rights advocates but seen as insufficient by ...
Helus Pharma announced fiscal 2026 financial results and progress on its Phase 3 trial for HLP003 in major depressive disorder, with topline data expe...
Helus Pharma completed a $50 million public offering to fund Phase 3 trials for depression and anxiety treatments, highlighting investor confidence in...
Helus Pharma announced the pricing of a $50 million public offering to fund Phase 3 trials for its depression treatment HLP003 and other programs, hig...
Helus Pharma announced that its Phase 3 APPROACH trial for HLP003 has surpassed 86% enrollment, keeping the study on track for topline data in Q4 2026...
Helus Pharma announced its Chief Medical Officer will participate in a fireside chat at the H.C. Wainwright Neuro Perspectives Conference, highlightin...
Craig Munro Wilson's 'Baptize America' examines the 1820 Campbell-Walker debate, arguing it shaped American religious identity and connects to modern ...
Helus Pharma issued a correction to its partnership announcement with TARA Mind, removing references to Veterans Exploring Treatment Solutions while r...
Helus Pharma strengthens its Scientific Advisory Board with renowned experts Dr. Robert Langer and Dr. Stephen Brannan, supporting its pipeline of nov...
Helus Pharma announces the immediate resignation of CEO Michael Cola and appointment of co-founder Eric So as interim CEO, as the company advances its...
Helus Pharma announced the appointment of Dr. Ken Kramer as senior vice president of medical affairs, bringing over two decades of neuroscience medica...
The launch of the first data center in Europe operating on a microgrid near Dublin addresses the growing energy demands of the digital economy by enab...
Helus Pharma announced positive Phase 2 topline results for HLP004, showing significant reduction in anxiety scores in adults with GAD who remained sy...
Helus Pharma appoints Dr. Freda Lewis-Hall, a veteran biopharmaceutical leader with over 40 years of experience, to its board and as chair of the Scie...
Helus Pharma reported that a single dose of SPL026 achieved statistically significant and clinically meaningful reductions in depressive symptoms vers...
Helus Pharma reported Q3 2025 financial results, highlighting progress in its Phase 3 program for major depressive disorder and Phase 2 program for ge...
Helus Pharma has appointed Michael Cola as CEO to lead the company through upcoming Phase 2 and Phase 3 data readouts for its novel serotonergic agoni...
